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Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently
investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose
that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
Toll-like receptors (TLRs), which sense
conserved molecular patterns from micro-
bial pathogens, trigger a cascade of events
characterized by the secretion of pro-
inflammatory cytokines that results in the
stimulation of innate and adaptive
immunity. Agonists of TLRs are therefore
of major interest for the immunotherapy
of cancer. Imiquimod, a small molecule
agonist of TLR7, is already successfully
used for the topical treatment of skin
neoplasias such as basal cell carcinoma.1 In
view of the potential use of TLR7 ligands
for the treatment of non-skin cancer, we
and others have investigated the ability of
TLR7 agonists to induce systemic immune
responses. A combined schematic view of
the anti-tumor activity of TLR7 agonists
as demonstrated by our recent work is
depicted in Figure 1. We have shown
that the systemic application of TLR7
ligands functionally activates both CD8+
T cells and NK cells, two major effector
cell types for anticancer responses.2
Furthermore, TLR7 activation blocks
the suppressive function of regulatory
T cells that contribute to cancer-associated
immune suppression.3 Finally, we have
shown that IFN-a produced by plasmacy-
toid dendritic cells upon TLR activation
reduces the immunosuppressive activity of
myeloid-derived suppressor cells (MDSC),
a cell population that accumulates in
cancer patients and suppresses T cell
responses.4 We have elucidated the com-
bined molecular basis for these effects by
demonstrating that they are mediated by
proinflammatory cytokines, in particular
IL-6, and type I interferon secreted by
dendritic cells following their activation
through TLR7.2-4 Thus, TLR7 agonists
appear to fulfill many of the requirements
for an effective systemic immunotherapy.
The few studies investigating systemic
application of agonists for TLR7 or its
close homolog TLR8 in cancer patients
have however shown little efficacy.5,6
Treatment in these studies consisted of
two to three weekly applications. Given
the fact that cytokine secretion is crucial
for the therapeutic effect of TLR7,7 we
speculated that systemic cancer therapy
with immune response modifiers might be
limited by a phenomenon called TLR
tolerance. TLR tolerance is characterized
by blunted cytokine secretion after repeti-
tive receptor stimulation and has been
described for several TLRs, including
TLR7.8 Indeed, we recently demonstrated
for the first time that TLR tolerance
influences the efficacy of TLR stimulation
for the immunotherapy of cancer.9 In this
study we analyzed the kinetics of repeated
TLR7 stimulation with the small molecule
agonist R848 in mice. We showed that
a single injection of R848 blocks the
cytokine response to a second stimulation
for a time frame beginning 48 h after the
first injection and lasting for up to five
days. In contrast, repeated stimulation
within the first 24 h resulted in an
enhanced response. These findings sug-
gested that injections every second to third
day, as performed in clinical studies of
TLR7 agonists, would maintain TLR7 in a
refractory state. We designed a protocol of
fractionated cancer therapy with R848 in
cycles separated by five day intervals to
take advantage of the initial receptor prim-
ing and to avoid tolerance. This protocol
blocked tumor growth in a murine cancer
model with a higher efficiency than the
schedule used in clinical studies, although
the cumulated dose was lower.9
We observed TLR7 tolerance in myeloid
dendritic cells, in which the secretion of
proinflammatory cytokines was inhibited,
but also in plasmacytoid dendritic cells,
where type I interferon secretion was sup-
pressed.9 We showed in vivo that tolerance
correlated well with decreasing levels of
IRAK-1, an essential adaptor molecule for
type I interferon and cytokine production.
Furthermore, tolerance was not restricted to
TLR7: we demonstrated the occurrence of
heterotolerance, since TLR7 stimulation led
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to blunted cytokine secretion by subsequent
TLR2, 4 and 9 stimulation. Given the
global occurrence of tolerance, our results
may impact all therapeutic approaches
relying on repetitive stimulation with
immune response modifiers.
Interestingly, in contrast to the secre-
tion block observed for proinflammatory
cytokines, secretion of the suppressive
cytokine IL-10 was enhanced in tolerized
dendritic cells. Although not causally
involved in the induction of TLR7
tolerance,9 IL-10 may also limit the
efficiency of immunotherapy. It was
recently demonstrated that IL-10 sup-
presses proinflammatory cytokine secre-
tion following simultaneous stimulation
of two independent TLR pathways, thus
reducing the number of tumor-specific
CD8+ T cells and impairing the efficiency
of cancer immunotherapy.10 It is probable
that during simultaneous stimulation of
two independent TLR pathways, both
are affected by tolerance induction
concomitantly. The application of a frac-
tionated schedule to prevent tolerance
in protocols employing combinatorial
stimulation may therefore prove beneficial
by both enhancing the secretion of proin-
flammatory cytokines and preventing high
production of IL-10. In conclusion, we
suggest that a careful evaluation of the
timing of TLR stimulation and the profile
of cytokines induced is essential for
effective systemic immunotherapy with
TLR agonists.
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Figure 1. Overview of the cellular mechanisms of TLR7-targeting therapy. DC: dendritic cell, Teff: effector T cells, Treg: regulatory T cell, MDSC: myeloid-
derived suppressor cell, NK: natural killer cell, ssRNA: single-stranded RNA.
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